As NSCLC becomes increasingly segmented by precision therapies, the patient advocacy landscape is evolving alongside it. Broad lung cancer organizations remain influential, but mutation-specific communities are becoming increasingly important voices in research, education, and patient support.

We see that while some pharma companies have built strong visibility across the PAG ecosystem, meaningful whitespace still exists.

The opportunity is not simply to engage more organizations, but to engage meaningfully-with a clear understanding of existing relationships, geographic relevance, and where differentiated partnerships can create the most value.

This analysis is designed to bring more visibility into this complex ecosystem to inspire new insights worth exploring in your PAG engagement strategy.